LOX and breast carcinoma: The similar activity of LIPO-EPI-LOX in 2D cultures was observed by reducing the drug concentration to as low as one-quarter of the plasma peak of anthracyclines (Supplementary Fig. 3C, D), suggesting the breast cancer cells reached drug saturation values.